CVS Health CEO David Joyner defended pharmacy benefit managers (PBMs), which are often accused of inflating drug prices, and instead pointed to pharmaceutical companies' 'monopolistic tendencies' as the primary driver of high costs in the U.S. Joyner's comments came during the company's fourth-quarter earnings call, a platform typically focused on financial performance. However, the unusual focus on PBMs reflects the growing scrutiny these middlemen are facing from lawmakers, regulators, and the public. Joyner argued that PBMs like CVS's Caremark are essential for offsetting rising healthcare costs, claiming they are the only part of the drug supply chain solely dedicated to lowering prices. He alleged that branded drug manufacturers engage in aggressive price hikes, citing a figure of $21 billion added in gross drug spending during the first three weeks of January. However, the pharmaceutical industry and lawmakers maintain that PBMs and insurers exploit negotiated rebates and discounts, pocketing the savings instead of passing them on to patients. PhRMA, the pharmaceutical industry's lobbying group, stated that PBMs are 'under intense, well-deserved scrutiny' and that investigations have revealed their role in driving up costs and reducing patient access to medications.
CVS Health CEO David Joyner defended controversial pharmacy middlemen, who are widely accused of inflating prescription medication prices, and instead accused manufacturers of 'monopolistic' practices that keep drug costs high in the U.S. Joyner, who stepped into the role in October, spent much of his opening remarks on the company's fourth-quarter earnings call discussing so-called pharmacy benefit managers , or PBMs.
It comes at a time when lawmakers on both sides of the aisle and President Donald Trump have signaled interest in cracking down on PBMs. David Joyner, a longtime CVS executive, speaks during a Senate Health, Education, Labor and Pensions Committee hearing in Washington, D.C., on May 10, 2023. Like his company's Caremark unit, which are widely accused of inflating prescription medication prices, and instead accused manufacturers of 'monopolistic tendencies' that keep drug costs high in the U.S. discussing so-called pharmacy benefit managers, or PBMs. It was atypical for CVS' quarterly call to begin that way, but comes at a time when lawmakers on both sides of the aisle and President Donald Trump have CVS owns Caremark, one of the nation's three largest PBMs that collectively administer roughly 80% of prescriptions in the U.S. Those middlemen negotiate rebates with drug manufacturers on behalf of insurers, create lists of medications known as formularies that are covered by insurance and reimburse pharmacies for prescriptions. But lawmakers and drugmakers alike argue that PBMs overcharge the plans they negotiate rebates for, underpay pharmacies and fail to pass on savings from those discounts to patients. Joyner acknowledged that rising health-care costs in the U.S. are pressuring patients, employers and the federal government. He blamed factors such as increased patient utilization of services, rising health-care provider costs, labor shortages and 'dramatic price hikes' for branded drugs. But he said PBMs like Caremark are 'one of the most powerful forces helping to offset rising health care costs,' claiming that they are the only part of the drug supply chain solely focused on lowering costs. 'Our work is a critical counterbalance to the monopolistic tendencies of drug manufacturers,' Joyner said. 'This is why PBMs are needed and why manufacturers fight so hard to limit our capabilities.' He alleged that branded manufacturers added $21 billion in annual gross drug spending in the first three weeks of January through their price hikes, but did not cite where the figure is from. Joyner added that multiple economists have estimated that PBMs generate net value for the U.S. health-care system, more than $100 billion a year. However, the pharmaceutical industry and lawmakers argue that PBMs and insurers pocket those savings from negotiated rebates and discounts rather than passing them to patients. In a statement on Wednesday, PhRMA, the nation's largest lobbying group for the pharmaceutical industry said PBMs are 'under intense, well-deserved scrutiny.' 'Bipartisan state attorneys general, policymakers in both Congress and state legislatures and the FTC are all investigating these health care conglomerates,' a PhRMA spokesperson said. 'They've all come to the same conclusion: PBMs are driving up costs and reducing access at the expense of patients, employers, and our health care system.
Pbms Pharmacy Benefit Managers Drug Prices Health Care Costs CVS Health Pharmaceutical Industry Antitrust
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FTC Report Alleges PBMs Inflated Specialty Drug Prices by $7.3 BillionA Federal Trade Commission report accuses CVS Health, Cigna, and UnitedHealth Group of overcharging for specialty generic drugs, generating $7.3 billion in excess revenue over six years. This practice, the FTC claims, inflated costs for consumers and insurers on important treatments for various conditions.
Read more »
UnitedHealth CEO Sees Growth in 2025 Despite CEO's MurderUnitedHealth Group CEO Andrew Witty expresses confidence in the company's future growth despite the tragic murder of the insurance unit's CEO, Brian Thompson. Witty acknowledges the public's reaction to the incident and emphasizes the company's commitment to improving healthcare access and affordability.
Read more »
Federal Trade Commission Report Exposes Massive Markups on Lifesaving Drugs by UnitedHealth and Other PBMsThe Federal Trade Commission (FTC) released a report alleging that the three largest pharmacy benefit managers (PBMs), Optum (UnitedHealth Group), CVS Caremark (CVS Health), and Express Scripts (Cigna), have made exorbitant profits by marking up prices of lifesaving drugs by hundreds or thousands of percent. The report sparked renewed attention following the assassination of Brian Thompson, CEO of UnitedHealth Group's insurance wing, UnitedHealthcare. CVS Caremark defended its practices, emphasizing its commitment to affordable healthcare and its efforts to combat pharmaceutical price gouging. The FTC is currently evaluating its next steps and may take legal action.
Read more »
PBMs Under Fire Again, But Despite Bipartisan Pressure Reforms May Be ElusiveAs Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months critical of pharmacy benefit managers.
Read more »
CEO.CA's 'Inside the Boardroom' Series Features Arizona Metals CEOCEO.CA, a leading investor social network, shares exclusive updates with CEOs of junior mining explorers. Their 'Inside the Boardroom' series features interviews with industry leaders, providing firsthand knowledge and insights into their vision, challenges, and strategies. This week's episode focuses on Duncan Middlemiss, CEO of Arizona Metals (TSX: AMC), discussing key catalysts including an updated resource estimate and a Preliminary Economic Assessment.
Read more »
Cizzle Brands CEO Joins CEO.CA's 'Inside the Boardroom' to Discuss Premium Beverage Market GrowthCEO.CA's popular interview series, 'Inside the Boardroom,' features John Celenza, CEO of Cizzle Brands (CBOE: CZZL), discussing the company's impressive entry into the premium beverage market. Cizzle Brands has generated nearly $5 million in sales in its first four months.
Read more »